Compare Raymond James Financial, Inc. (RJF) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs BIO-TECHNE Corp — how do they compare? Raymond James Financial, Inc. trades at $167.57 (market cap $32.73B), while BIO-TECHNE Corp trades at $71.78 (market cap $11.16B). The key difference: Raymond James Financial, Inc. is far larger — about 2.9× BIO-TECHNE Corp's market cap, and Raymond James Financial, Inc. pays the higher dividend (1.29%). Which is the better fit depends on your goals.
| RJF | TECH | |
|---|---|---|
Market Cap | $32.73B | $11.16B |
Sector | Financials | Health |
52-Week High | $176.43 | $72.12 |
52-Week Low | $140.89 | $43.31 |
Dividend Yield | 1.29% | 0.45% |
Enterprise Value | — | $11.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $167.93, down 0.26% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows strong fundamental performance with 2025 revenue of $13.84B and net income of $2.14B, supported by a P/E of 15.89. Analyst consensus is positive with a $176.83 price target, and recent news highlights advisor recruitment driving growth.
The outlook for RJF remains favorable due to earnings momentum and institutional interest, though risks include expense pressures and market volatility. The stock presents a growth opportunity with solid valuation support, but investors should monitor cost management and macroeconomic factors that could impact financial services performance.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
